State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1, Xiannongtan Street, Xicheng District, Beijing 100050, China.
Department of Medicinal Chemistry, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
J Med Chem. 2020 Aug 13;63(15):7986-8002. doi: 10.1021/acs.jmedchem.9b01865. Epub 2020 Apr 8.
The activation of nuclear factor erythroid 2-related factor 2 (Nrf2) is believed to combat both oxidative stress and inflammation as a promising strategy to treat chronic diseases. Recently, directly inhibiting the protein-protein interaction (PPI) between Nrf2 and Kelch-like ECH associated protein 1 (Keap1) has emerged as an attractive strategy to activate Nrf2 in organisms. The current development of Keap1-Nrf2 PPI inhibitors is mainly based on the interaction between Keap1 and the Nrf2 ETGE motif. However, a group of proteins that feature an ETGE motif similar to that of Nrf2 have emerged as new substrates of Keap1 over the past decade. In this Perspective, we focus on the potential off-target actions of current Keap1-Nrf2 PPI inhibitors and discuss their impact on future drug development. We also propose that a DLGex-based strategy aiming to inhibit the Keap1-Nrf2 DLGex interaction would help the development of small molecules with better target selectivity.
核因子红细胞 2 相关因子 2(Nrf2)的激活被认为是对抗氧化应激和炎症的有前途的策略,可用于治疗慢性疾病。最近,直接抑制 Nrf2 和 Kelch 样 ECH 相关蛋白 1(Keap1)之间的蛋白-蛋白相互作用(PPI)已成为激活生物体中 Nrf2 的一种有吸引力的策略。目前 Keap1-Nrf2 PPI 抑制剂的开发主要基于 Keap1 与 Nrf2 ETGE 基序之间的相互作用。然而,在过去十年中,一组具有与 Nrf2 相似 ETGE 基序的蛋白质已成为 Keap1 的新底物。在本观点中,我们重点关注当前 Keap1-Nrf2 PPI 抑制剂的潜在脱靶作用,并讨论它们对未来药物开发的影响。我们还提出,基于 DLGex 的策略旨在抑制 Keap1-Nrf2 DLGex 相互作用,将有助于开发具有更好靶选择性的小分子。